The LinkedIn profile for Andrew Froude states that he worked at...

The LinkedIn profile for Andrew Froude states that he worked at OIL from July 2016 until August 2018
According to his current profile on LinkedIn he has gone from OIL.
If he has gone from OIL and obviously he has why not just tell us and the market, surely this is just plain simple ASX governance 101.
Graham Mutton as you are a Director now how about delivering on these most basic requirements.
What else are we not being told.
This is disappointing that we have to find this sort of important information about OIL through the back door.
Also I found this ASX Announcement from 16 April 2018 which makes special mention of Andrew Froude's efforts.
It was important enough to announce Andrew Froude's appointment as a Senior Executive and his progress with ViewnVivo, it is reasonable to expect that we should know about his departure.
OIL Directors once again this is not good enough.


ASX AnnouncementOptiscan Imaging Limited (ASX:OIL)
Successful European conference participation
16 April 2018
Optiscan Imaging Limited (ASX:OIL; “Optiscan” or “The Company” is pleased to provide shareholders with this market update following the Company’s successful participation at the EMIM Conference in Spain last month.
Successful participation at the EMIM Conference
The 13th European Molecular Imaging Meeting (EMIM), held in Spain last month attracted more than 700 delegates. The conference provided Optiscan with the opportunity to reinforce our re-entry to the preclinical research market following our participation at the World Molecular Imaging Congress in the USA last September.
As a platinum sponsor at EMIM, Optiscan utilised prime exhibition space, multiple advertising mediums and a presentation opportunity to connect with potential customers and European distribution partners.

The conference was attended by Andrew Froude (General Manager - Preclinical Research Products) and Peter Delaney (CTO) along with representatives of the Optiscan distributors of our leading high-resolution point scanning confocal technology, ViewnVivo.

Interest from conference delegates in Optiscan’s ViewnVivo technology was strong with 39 leads captured including 28 identified as potential customers. Six potential customers have already requested meetings and product demonstrations.

“This is a direct reflection of the continued tremendous efforts of Andrew Froude over the past 20 months, having driven the ViewnVivo product development and successfully created penetration into the market in this space” said Executive Chairman Alan Hoffman.

Andrew Froude is also attending events and meeting with customers in China, USA and Canada over the next month to continue the push into these crucial markets for ViewnVivo highlighting the value of a continued good relationship with our distributors in North America and China.

Optiscan looks forward to sharing more updates with the market on a range of developments in coming weeks.
Enquiries:
Alan Hoffman
Executive Chairman
E: [email protected]